Health care sector news

Health care sector news. Deduplicated factual headlines, scored for importance, with entity sentiment and the companies, sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-30 15:19:36 UTC#546580newconfirmednews

US FDA approves removal of black box warnings from three estradiol transdermal patches

reutersimportance 0.50trust 0.90U.S. Department of Health and Human Services +0.40U.S. Food and Drug Administration +0.40National Institute of Child Health and Human Development 0+1 entities

2026-10-30 13:53:00 UTC#546134updateconfirmednews

Acumen Pharmaceuticals halts development of lead Alzheimer's drug sabirnetug after Phase 2 failure, explores strategic options

dow_jonesimportance 0.70trust 0.90Acumen Pharmaceuticals, Inc. -0.90sabirnetug -0.90Alzheimer's disease -0.20

2026-10-30 13:23:00 UTC#545897newconfirmednews

Health care sector news

US FDA approves removal of black box warnings from three estradiol transdermal patches

Acumen Pharmaceuticals halts development of lead Alzheimer's drug sabirnetug after Phase 2 failure, explores strategic options

Pelthos to acquire Castle Creek Biosciences in merger with $57.5M+ PIPE financing

Medi Assist reports Q2 net profit of Rs 215.76m and approves Rs 425-per-share tender offer buyback

Alphatec shares drop 32% as biologics sales slump drives Q3 earnings miss and guidance cut

Acumen Pharmaceuticals shares drop following mid-stage clinical trial setback for Alzheimer's drug candidate

Viatris commences tender offer to acquire all outstanding shares of Pacira BioSciences

iRadimed Corporation Q3 2026 EPS corrected to 51 cents from previously reported 55 cents

iRadimed Corporation Q3 2026 revenue $24.2M, GAAP EPS $0.51, declares $0.20 quarterly dividend

Max Healthcare Q2 PAT rises 10% to ₹448 crore on 20% revenue growth

S&P 500 futures fall 1.1% as tech earnings from Amazon and Intel weigh on market sentiment

AbbVie Q3 2026 Adj. EPS $3.82 vs $3.74 est., Revenue $17.40B vs $17.34B est., Raises FY Guidance

AbbVie raises quarterly dividend to $1.82 per share from $1.73

AbbVie raises 2026 adjusted EPS guidance to $13.95-$13.99

AbbVie issues 2026 adjusted EPS guidance of $13.76 to $13.96

AbbVie Q3 revenue $17.4B beats estimates; company raises full-year profit outlook and quarterly dividend

AbbVie reports Q3 2026 total revenue of $17.4 billion

AbbVie reports Q3 2026 global Skyrizi revenue of $5.78 billion

AbbVie Q3 2026 Rinvoq revenue $2.71 billion, up 23.9% year-over-year

AbbVie Q3 2026 global immunology portfolio net revenue $9.165 billion, up 16.5% year-over-year